estigmasterol

Stigmasterol: A Comprehensive Encyclopedic Reference

1. Identity: Chemical and Botanical Profile

1.1 Nomenclature and Chemical Structure

Stigmasterol (C₂₉H₄₈O, stigmasta-5,22-dien-3-ol), also known as wulzen anti-stiffness factor or stigmasterin, is a phytosterol — a steroid belonging to the class of tetracyclic triterpenes — having a structure similar to that of cholesterol. Its systematic IUPAC name is (3β,22E)-stigmasta-5,22-dien-3-ol, and it carries the CAS registry number 83-48-7. Chemically, stigmasterol is a steroid analogue having a hydroxyl group at the C-3 position of the cyclopentanoperhydrophenanthrene ring with unsaturation at 5–6 and 22–23 carbons, methyl groups at the 10th, 13th and 25th carbons, and an ethyl substitution at the 24th carbon. More specifically, stigmasterol (stigmasta-5,22-dien-3β-ol, C₂₉H₄₈O) is characterized by the presence of a hydroxyl group in position C-3 of the steroid skeleton, double bonds in positions 5,6 of the B ring and in position 22,23 in the alkyl substituent, as well as an isoprenyl tail. The common 29-carbon desmethylsterol stigmasterol, which includes both C5,6 and (trans) C22,23 double bonds, is designated as Δ5,22E.

This phytosterol is C24-alkylated cholesterol, operating primarily as a common constituent of the cell membrane and playing a central role in membrane stability. It is structurally distinguished from the closely related β-sitosterol by the presence of the additional trans-double bond at C22–23 in the side chain. Phytosterols are chemically classified as triterpenes, a class of terpenes composed of six isoprene units.

1.2 Botanical Sources

Stigmasterol is an unsaturated phytosterol belonging to the class of tetracyclic triterpenes. It is one of the most common plant sterols, found in a variety of natural sources, including vegetable fats or oils from many plants. Stigmasterol occurs in the plant fats or oils of numerous plants — such as soybean, calabar bean, and rapeseed — and in herbs used in herbalism practices, including the Chinese herb Ophiopogon japonicus (Mai men dong) and Mirabilis jalapa. It is also a constituent of various vegetables, legumes, nuts, seeds, and unpasteurized milk. Pasteurization inactivates stigmasterol. Edible oils contain higher amounts than vegetables.

Stigmasterol is the main ingredient in several plant extracts, including the Chinese medicinal herb Ophiopogon japonicus (Maidong in Chinese). It was also found to be the major ingredient isolated from the leaf extract of Annona muricata L. and Aegle marmelos L. from India. Most plant meals contain varying amounts of phytosterols, although unprocessed seed oils have been found to have the highest concentration. Generally, fresh fruits, vegetables, seeds, and vegetable oils are good sources of sterols.

The human body cannot naturally produce this plant sterol; therefore, it is only available through foods and diets such as vegetable oils (rapeseed, soybean, and calabar bean oils), cereals, and other vegetables, unpasteurized milk, seeds, medicinal plants, as well as nuts and legumes.

1.3 Biosynthesis in Plants

Stigmasterol is synthesized from beta-sitosterol by the cytochrome P450 CYP710A1 via C22 desaturation. The resulting products undergo a series of reactions analogous to ergosterol — C5-desaturation, Δ7-reduction, and Δ24-reduction to yield sitosterol — after which final desaturation of C22 of sitosterol yields stigmasterol. Accumulation of the phytosterol stigmasterol is a significant plant metabolic process that occurs upon bacterial leaf infection; it is synthesized from beta-sitosterol by the cytochrome P450 CYP710A1 via C22 desaturation.

1.4 Common Preparations and Forms

Within the European Union, stigmasterol is listed as a food additive under the number E499, and may be used to boost phytosterol levels in the production of foods, thereby helping to improve LDL-cholesterol levels. It is a food additive in manufactured food products in the United Kingdom and European Union.

Due to its nonpolar nature, stigmasterol is isolated from different plant parts using solvents higher in the elutropic series, i.e., nonpolar solvents. Although the synthesis of stigmasterol occurs in various natural sources, it has proven difficult to isolate and purify economically. Distillation, solvent extraction, supercritical fluid extraction (SFE), and crystallization are among the techniques employed.

The compound stigmasterol is employed in various chemical manufacturing processes intended to generate various semi-synthetic and synthetic components for the pharmaceutical industry. Due to the presence of a π system and a hydroxyl group, stigmasterol is readily derivatized through substitution and addition reactions, allowing for the synthesis of a wide variety of stigmasterol derivatives.

2. Historical Discovery and Traditional Use

2.1 Discovery and Early Scientific History

It is a secondary metabolite that was isolated for the first time in 1906 in Calabarbohne (Physostigma venenosum) by Adolf Wind Form and A. Hauth. Stigmasterol is significant in its own right due to its distinctive function in plant science, comparable to that of ergosterol in fungi and cholesterol in animal cells.

Once called Wulzen factor in the mid-20th century, stigmasterol was discovered by the University of California physiologist Rosalind Wulzen (born 1886). The "anti-stiffness factor" designation arose from Wulzen's animal research suggesting that the compound prevented calcification-related joint stiffness, although this designation predated modern rigorous clinical evidence.

2.2 Pharmaceutical History: Cortisone and Steroid Synthesis

Unique interdisciplinary teams at Upjohn enabled the company to rapidly develop and commercialize processes for preparing both cortisone (starting in 1952) and hydrocortisone (1953) from stigmasterol. Upjohn had been producing progesterone for years from stigmasterol, an inexpensive and abundant compound obtained from soybeans. It was introduced as a precursor by Percy Lavon Julian for industrial large-scale manufacture of semisynthetic progesterone. It is also used as a precursor of vitamin D3.

Stigmasterol acts as a precursor in the synthesis of progesterone and as an intermediate in the biosynthesis of androgens, estrogens, and corticoids. Numerous hormones, including estrogen, progesterone, corticoids, and androgen, are synthesized from stigmasterol.

2.3 Traditional Herbal and Ethnomedicinal Context

Historically, stigmasterol was isolated from Physostigma venenosum, a plant used in traditional African medicine. It is widely distributed in various plant-based foods and materials, including soybean, calabar bean, and other legumes.

Stigmasterol occurs in the plant fats or oils of numerous plants such as soybean, calabar bean, and rapeseed, and in herbs used in herbalism practices, including the Chinese herb Ophiopogon japonicus (Mai men dong) and Mirabilis jalapa. In Chinese medicine, Ophiopogon japonicus has been used historically for lung and heart conditions, and stigmasterol is now recognized as one of its active phytochemical constituents. Traditional practices using medicinal plants are an important part of the primary health care system. Since ancient times, plants have been used as medicine, foods, agrochemicals, and pharmaceuticals by large numbers of people.

There are currently around 250 plant sterols that differ in function and accessibility, but stigmasterol has become a unique compound due to its diverse pharmacological properties. It bears noting that while stigmasterol was a constituent of plants used across African, Asian, and traditional Western herbal systems, the compound itself was not identified or isolated by traditional practitioners — its presence in those plants was only established through 20th-century phytochemical analysis.

3. Key Constituents, Chemistry, and Mechanisms of Action

3.1 Structural Relationship to Cholesterol

ABCG5 and ABCG8 genes encode a heterodimer sterol efflux transporter, ABCG5/8, which plays a critical role in transporting cholesterol and phytosterols outwards across the apical membranes of enterocytes and hepatocytes, thus preventing dietary phytosterols from accumulating in the body. Phytosterols share many structural similarities with cholesterol, but unlike cholesterol, phytosterols cannot be synthesized in mammalian cells. Despite being present at comparable quantities with cholesterol in typical human diets, phytosterols are largely prevented from intestinal absorption and are effectively excreted via bile, with only trace amounts of phytosterols found in healthy individuals (<0.5 mg/dL plasma).

3.2 Cholesterol-Lowering Mechanism

Like other phytosterols, stigmasterol is poorly absorbed due to the activity of the ABCG5/ABCG8 sterol transporter, the body's principal defense against the accumulation of non-cholesterol sterols. In the absence of functional ABCG5/ABCG8, phytosterol bioavailability increases significantly, an effect blocked by pharmacologic or genetic inactivation of the primary mediator of cholesterol absorption, NPC1L1 (Niemann Pick C 1-like 1), in mice and humans. This indicates that phytosterols, including stigmasterol, cross the brush border membrane, but are returned to the intestinal lumen by ABCG5/ABCG8.

The exact mechanism of action for cholesterol-lowering properties is not fully known, but because their structure is similar to that of cholesterol, phytosterols compete for solubilization in micelles and therefore inhibit intestinal absorption of both dietary and endogenous cholesterol. Dietary stigmasterol may directly regulate the mRNA expression of NPC1L1, whereas oxidized stigmasterol may reduce the mRNA expression of sterol regulatory element-binding protein 2 and act as a Liver X receptor α agonist, thereby reducing the mRNA expression of NPC1L1.

3.3 Anti-Inflammatory Mechanisms

The anti-inflammatory properties of phytosterols involve the production of anti-inflammatory cytokines, the decrease in inflammatory mediator release, and the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). In molecular docking studies, stigmasterol showed a potent antagonist influence on COX-1, COX-II, CAT, and INF-gamma, with binding affinities of −8.9, −8.9, −8.8, and −8.4 kcal/mol, respectively.

3.4 Anticancer Mechanisms

Stigmasterol from plants and algae is a promising molecule in the development of drugs for cancer therapy by triggering intracellular signaling pathways in numerous cancers. It acts on the Akt/mTOR and JAK/STAT pathways in ovarian and gastric cancers. In gastric cancer cell lines, stigmasterol suppressed the proliferation of SGC-7901 and MGC-803 cells, probably via inhibiting the Akt/mTOR signaling pathway and inducing apoptosis and autophagy.

3.5 Anti-Diabetic Mechanisms

Stigmasterol exerts anti-diabetic effects by reducing fasting glucose, serum insulin levels, and oral glucose tolerance. At the molecular level, stigmasterol can specifically bind to the glucose transporter 4 (GLUT4), functioning as a conduit to facilitate glucose entry into cells, thereby substantially augmenting glucose uptake and use. This mechanism effectively mitigates insulin resistance and enhances blood glucose regulation.

3.6 Neuroprotective Mechanisms

Reactive oxygen species (ROS) regulation contributes to the neuroprotective effects of stigmasterol, as well as effects on dopamine depletion and acetylcholinesterase inhibition. It was found that stigmasterol decreases the cerebral activity of amyloidogenic enzymes in mice.

3.7 Cholesterol Homeostasis Disruption at High Concentrations

Accumulation of stigmasterol, and perhaps other bioactive sterols, downregulates the cholesterol regulatory machinery, resulting in reduced cholesterol biosynthesis. This effect is relevant primarily in the context of pathological phytosterol accumulation (see Safety section).

4. Scientific Evidence by Area of Use

4.1 Cardiovascular Health and LDL Cholesterol Reduction

Clinical Evidence (Moderate–Strong for the phytosterol class; limited data specific to stigmasterol alone):

As one of the major phytosterols, stigmasterol is included among sterol compounds in the diet having potential to reduce the risk of cardiovascular diseases. Consumption of 2 grams per day of plant sterols is associated with a reduction in blood LDL cholesterol of 8–10%, possibly lowering cardiovascular disease risk.

Clinical studies consistently indicate that the intake of phytosterols (2 g/day) is associated with a significant reduction (8–10%) in levels of low-density lipoprotein cholesterol. Several guidelines recommend the intake of 2 g/day of plant sterols and/or stanols to reduce LDL-cholesterol levels. As the typical Western diet contains only about 300 mg/day of phytosterols, foods enriched with phytosterols are usually used to achieve the recommended intake.

Supplementation of 2 g per day of phytosterols reduced total cholesterol and LDL-c, but the effect of phytosterol supplementation in reducing LDL-c can be influenced by several factors, among them the time and frequency of administration, whether given as a single or fractionated dose, and the occasion of ingestion relative to the type of meal. The best effect of supplementation is seen when administered with main meals and divided into twice a day.

Important caveat: Although phytosterols decrease LDL-cholesterol levels, there is no evidence that they reduce the risk of cardiovascular diseases; on the contrary, some studies suggest an increased risk of atherosclerosis with increasing serum levels of phytosterols. The clinical evidence regarding their lipid-lowering and anti-inflammatory effects remains inconsistent.

It is critical to note that the clinical trials on LDL reduction generally study mixed phytosterol preparations or plant stanol/sterol extracts, rather than isolated stigmasterol specifically. The evidence for stigmasterol as an isolated compound on human cardiovascular outcomes has not been established in randomized controlled trials.

4.2 Anti-Osteoarthritic Effects

Evidence: Preclinical (in vitro and animal); no published human clinical trials as of the time of writing.

Stigmasterol (STM), one of the main active components of Achyranthes bidentata, has been shown to effectively inhibit proinflammatory factors and matrix degradation in chondrocytes. STM reduced IL-1β-induced ATDC5 cell damage and ferroptosis through SREBF2, and enhanced the inhibitory effect of ferroptosis inhibitors on IL-1β-induced cell injury. The data suggest that STM attenuated chondrocyte injury induced by IL-1β by regulating ferroptosis via down-regulation of SREBF2, and may have potential as a novel therapeutic method for knee osteoarthritis.

In vitro studies tested the possible beneficial effects of stigmasterol combined with mesenchymal stem cell-conditioned medium (MSC-CM). The results showed a significant decrease in MMP-3, MMP-13, and ADAMTS-5, as well as a significant increase in the expression of collagen type II, alpha 1 (COL2A1). The combined therapy elicited a greater anticatabolic effect by suppressing IL-1β-induced NF-κB activation, as indicated by insignificant phosphorylation of p65 and IκBα subunits.

Research into intra-articular delivery systems for stigmasterol in osteoarthritis rat models has been explored in preclinical pilot studies, but clinical translation to humans remains outstanding.

4.3 Anticancer Properties

Evidence: Predominantly in vitro and some in vivo (animal); no human clinical trial data.

Stigmasterol is a phytosterol derived from multiple herbaceous plants and has received much attention for its various pharmacological effects. Multiple studies have revealed that stigmasterol holds promise as a potentially beneficial therapeutic agent for malignant tumors because of its significant anti-tumor bioactivity.

Combining these results, investigators believed that stigmasterol induced apoptosis and protective autophagy in gastric cancer cells while inhibiting the Akt/mTOR signaling pathway, and they suggested stigmasterol was likely to become a potential anticancer agent in future gastric cancer treatment. Stigmasterol significantly suppressed tumor growth, tumor angiogenesis, and macrophage recruitment in cholangiocarcinoma (CCA) xenograft models by inhibiting the production of inflammatory cytokines, proving the important role of stigmasterol in suppressing tumor growth and endothelial morphogenesis.

Limitation explicitly stated in the literature: Most of the current findings are derived from in vitro or in vivo animal experiments but have rarely been clinically translated, requiring clinical trials to explore the practical applications of stigmasterol in human bodies.

4.4 Anti-Diabetic and Metabolic Effects

Evidence: In vitro and animal studies; no robust human clinical trial data specific to stigmasterol.

Findings from various in vitro and in vivo studies have revealed the potential of stigmasterol in treating various diseases, including cancer, diabetes, neurological disorders, and inflammatory conditions. The regulatory mechanisms of stigmasterol in glucose and lipid metabolism are gradually being elucidated in the context of the prevention and treatment of metabolic disorders. Stigmasterol also plays a crucial role in diseases that are strongly associated with lipid metabolism, such as obesity and non-alcoholic fatty liver disease (NAFLD).

4.5 Neuroprotective Effects

Evidence: Preclinical (animal and cell-based); no human clinical trials.

In particular, stigmasterol can perform neuroprotective functions in disorders of the central nervous system, such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis/parkinsonism dementia. Various biological and pharmaceutical properties of stigmasterol have been shown, such as analgesic properties, maintaining psychiatric status, and improving learning and memory abilities.

These findings are currently based entirely on preclinical data. No human trials have been conducted to evaluate stigmasterol's efficacy in neurodegenerative conditions.

4.6 Anti-Inflammatory Effects

Evidence: In vitro and animal models; no standalone human clinical trials for isolated stigmasterol.

Stigmasterol has significant anti-arthritis and anti-inflammatory effects. Its potential advantages in asthma were explored in IL-13-induced BEAS-2B cells and asthmatic mice. A 2026 study evaluated the anti-inflammatory effect of Acanthospermum hispidum leaves and confirmed the traditional use of that plant on diseases linked to inflammation, with stigmasterol as a key isolated metabolite.

4.7 Antiparasitic, Antifungal, and Antibacterial Effects

Evidence: In vitro and limited in vivo (animal); no human clinical evidence.

Antiparasitic activities of stigmasterol have been demonstrated against certain strains of parasites such as Trypanosoma congolense (in vivo) and on promastigotes and amastigotes of Leishmania major (in vitro). Some stigmasterol-rich plants were able to inhibit Candida albicans, C. virusei, and C. tropicalis at low doses.

5. Body Systems and Health Areas of Association

Based on the totality of in vitro, in vivo, and (where applicable) clinical research, stigmasterol has been studied across a broad range of body systems:

• Cardiovascular system: As one of the major phytosterols, stigmasterol is included among sterol compounds in the diet having potential to reduce the risk of cardiovascular diseases. It contributes to LDL-cholesterol reduction as part of total dietary phytosterol intake.
• Musculoskeletal system (joints and cartilage): In vitro and in vivo studies have demonstrated the anti-osteoarthritis properties of stigmasterol. Its effects on chondrocyte ferroptosis and matrix-degrading enzymes place it within musculoskeletal research.
• Oncology / cell signaling: The anti-inflammatory, antioxidant, anticancer, neuroprotective, and hypolipidemic activities of stigmasterol have been discussed in peer-reviewed reviews.
• Endocrine and metabolic system: The regulatory mechanisms of stigmasterol in glucose and lipid metabolism are gradually being elucidated in the context of prevention and treatment of metabolic disorders.
• Central nervous system: Stigmasterol can perform neuroprotective functions in disorders of the central nervous system, such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis/parkinsonism dementia.
• Immune system: Stigmasterol has been identified as having immunomodulatory properties, alongside anticancer, anti-osteoarthritis, anti-inflammatory, anti-diabetic, antiparasitic, antifungal, antibacterial, antioxidant, and neuroprotective properties.
• Respiratory system: Stigmasterol has significant anti-arthritis and anti-inflammatory effects, and its potential advantages in asthma were explored in IL-13-induced cell models and asthmatic mice.
• Pharmaceutical substrate: Upjohn teams developed and commercialized processes for preparing both cortisone (starting in 1952) and hydrocortisone (1953) from stigmasterol, establishing its central historical role as a pharmaceutical precursor.

6. Dosage Forms and Doses Reported in Studies

Stigmasterol is not typically sold or studied as a single-ingredient supplement at a defined clinical dose. As an isolated compound, it is investigated primarily in preclinical settings. Dosage information pertains largely to phytosterol mixtures (of which stigmasterol is one component) in clinical contexts:

• Dietary phytosterol intake (Western diet): The typical Western diet contains only about 300 mg/day of phytosterols. The regular daily intake of phytosterols ranges from 150–350 mg.
• Clinically studied dose for LDL reduction: Clinical studies consistently indicate that the intake of phytosterols (2 g/day) is associated with a significant reduction (8–10%) in levels of LDL-cholesterol. Several guidelines recommend the intake of 2 g/day of plant sterols and/or stanols in order to reduce LDL-cholesterol levels.
• Dose range investigated in clinical trials: The dose in clinical trials is around 2–4 g/day, and the reduction in LDL-cholesterol is approximately 10%.
• Guideline-supported dose range and enhanced efficacy: Current guidelines recommend ≥2 g/day of phytosterols to achieve LDL-C reductions, with some trials suggesting enhanced efficacy at doses >2.5–3 g/day.
• Maximum effective dose (mixed phytosterols/stanols): A daily intake of 1.5 to 2.4 g of plant stanols has been scientifically evaluated to lower LDL-C by 7 to 10% in different populations, ages, and diseases. Based on earlier studies, a general understanding is that no further reduction may be achieved with intakes in excess of approximately 2.5 g/day.
• Preclinical (in vitro/animal) dosing: In animal inflammation models, the peak percentage inhibition of extract occurred at a dose of 100 mg/kg in rodent studies of anti-inflammatory activity. Such doses are not directly translatable to human use.

No specific regulated human daily dose exists for stigmasterol as an isolated compound. All clinical dose recommendations apply to mixed phytosterol preparations consumed with meals.

7. Safety Considerations and Notable Interactions

7.1 Normal Absorption and Physiological Handling

Like other phytosterols, stigmasterol is poorly absorbed due to the activity of the ABCG5/ABCG8 sterol transporter, the body's principal defense against the accumulation of non-cholesterol sterols. Despite being present at comparable quantities with cholesterol in typical human diets, phytosterols are largely prevented from intestinal absorption and are effectively excreted via bile, with only trace amounts of phytosterols remaining in healthy individuals (<0.5 mg/dL plasma).

7.2 Sitosterolemia (Phytosterolemia): A Rare Genetic Disorder

Sitosterolemia is a rare autosomal recessive disorder of non-cholesterol sterol metabolism, caused by mutations of the ABCG5 or ABCG8 transporter genes. This results in hyperabsorption and decreased biliary excretion of non-cholesterol sterol from the gastrointestinal tract. Affected individuals have excessive accumulation of plant sterols and 5α-saturated stanols in plasma and tissues, resulting in premature cardiovascular disease.

In an individual with sitosterolemia, increased plasma concentrations of plant sterols (especially sitosterol, campesterol, and stigmasterol) are observed if the diet includes plant-derived food containing plant sterols, once the plant sterols have accumulated in the body. Patients classically present with tendinous and tuberous xanthomas and premature coronary atherosclerosis, but may also develop hemolysis, splenomegaly, platelet abnormalities, and arthritis. Treatment recommendations include a diet low in shellfish sterols and plant sterols (vegetable oils, margarine, nuts, seeds, avocados, and chocolate) and use of the sterol absorption inhibitor ezetimibe.

7.3 Cardiac Risk from Stigmasterol Accumulation

A significant finding from preclinical research concerns the consequences of pathological accumulation: cardiac injury and increased mortality were reported despite a 50% reduction in plasma cholesterol in a mouse model of phytosterolemia, a disease characterized by elevated levels of dietary plant sterols in the blood. Studies showed that accumulation of stigmasterol, one of the phytosterol species, leads to left ventricle dysfunction, cardiac interstitial fibrosis, and macrophage infiltration without atherosclerosis, and increased mortality. The proposed pathological mechanism linking clinical sitosterolemia to cardiovascular outcomes primarily involves phytosterol-induced cardiac fibrosis rather than cholesterol-driven atherosclerosis.

These findings suggest that elevated concentration of phytosterols represents an independent risk factor for cardiovascular disease. This risk is specifically relevant to individuals with sitosterolemia or other conditions causing abnormal phytosterol accumulation, not to individuals with normal ABCG5/ABCG8 transporter function consuming dietary amounts.

7.4 Relationship to Cardiovascular Outcomes in the General Population

Although phytosterols decrease LDL-cholesterol levels, there is no evidence that they reduce the risk of cardiovascular diseases; on the contrary, some studies suggest an increased risk of atherosclerosis with increasing serum levels of phytosterols. There is controversy about treatment with statins inducing further increase in plasma non-cholesterol sterols, raising concerns about the safety of supplementation of plant sterols in conjunction with such drugs.

7.5 Interaction with Statins

Initial observations showed that pravastatin and lovastatin increased cholestanol and plant sterol absorption markers, such as sitosterol, campesterol, stigmasterol, avenasterol, brassicasterol, and ergosterol. This observation raised questions about whether statin therapy, by affecting sterol metabolism, could elevate circulating phytosterol levels. The clinical significance of this interaction in the general population remains an area of ongoing investigation.

7.6 Effect of Pasteurization

Pasteurization will inactivate stigmasterol in dairy products, a relevant consideration for those seeking dietary sources of this phytosterol from milk.

7.7 Lipinski's Rule of Five and Drug-like Properties

In molecular pharmacology assessments, stigmasterol was observed to obey Lipinski's rule of five except for MLOGP, indicating general drug-likeness with the caveat that its lipophilicity index (MLOGP) falls outside typical oral drug parameters — a characteristic consistent with its known limited aqueous solubility and low oral bioavailability.

8. Current Research Landscape and Evidence Limitations

Stigmasterol is a plant-derived phytosterol that has attracted considerable attention because of its diverse biological activities and potential therapeutic applications. In recent reviews, its chemical properties, biosynthesis, and biological effects are exhaustively summarized.

The overarching limitation across all areas of stigmasterol research is the near-complete absence of human clinical trials evaluating the compound in isolation. Most of the current findings are derived from in vitro or in vivo animal experiments but have rarely been clinically translated, requiring clinical trials to explore the practical applications of stigmasterol in human bodies. The areas where the strongest human-relevant evidence exists — LDL-cholesterol reduction — pertain to phytosterol mixtures, not to stigmasterol tested alone.

Findings from various in vitro and in vivo studies have revealed the potential of stigmasterol in treating various diseases, including cancer, diabetes, neurological disorders, and inflammatory conditions. The mechanisms underlying these effects are being examined, particularly emphasizing the regulation of key signaling pathways and molecular targets. However, translating these mechanisms into proven clinical therapies is an unmet challenge for the field.

References

• Ayelign B, et al. "Health Benefits and Pharmacological Properties of Stigmasterol." Antioxidants 11, no. 10 (2022): 1912. PMC9598710.
• Research Progress on the Therapeutic Mechanisms of Stigmasterol for Multiple Diseases. PMC12073555.
• Zhang X, et al. "Advances in Stigmasterol on its anti-tumor effect and mechanism of action." Frontiers in Oncology 12 (2022): 1101289. PMC9791061.
• Stigmasterol alleviates allergic airway inflammation and airway hyperresponsiveness in asthma mice through inhibiting substance-P receptor. PMC9930798.
• Tao R, et al. "Stigmasterol accumulation causes cardiac injury and promotes mortality." Communications Biology (2019). PMC6335236.
• Stigmasterol stimulates transintestinal cholesterol excretion independent of liver X receptor activation in the small intestine. PMC7199294.
• Plat J, et al. "Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases." Nutrients (2017). PMC5729784.
• In vitro cytotoxic effect of stigmasterol derivatives against breast cancer cells. BMC Complementary Medicine and Therapies (2023). PMC10496295.
• Mo Z, Xu P, Li H. "Stigmasterol alleviates interleukin-1beta-induced chondrocyte injury by down-regulating sterol regulatory element binding transcription factor 2 to regulate ferroptosis." Bioengineered 12, no. 2 (2021): 9332–40. PMC8810005.
• Calpe-Berdiel L, et al. "Phytosterols and phytosterolemia: gene–diet interactions." Current Vascular Pharmacology (2011). PMC3040800.
• Disruption of cholesterol homeostasis by plant sterols. PMC516266.
• Effect of plant sterols on the lipid profile of patients with hypercholesterolaemia. Randomised, experimental study. PMC3180270.
• Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence. PMC3543226.
• Comparative effects of dietary stigmasterol and oxidised stigmasterol on cholesterol absorption and metabolism in mice. PMC12797071.
• Patel SB. "Sitosterolemia." In: GeneReviews®. NCBI Bookshelf. National Institutes of Health.
• Sitosterolemia. In: Endotext. NCBI Bookshelf. National Institutes of Health.
• A comprehensive update on phytochemistry, analytical aspects, medicinal attributes, specifications and stability of stigmasterol. Steroids (2023). ScienceDirect.
• Phytosterols and phytostanols in context: From physiology and pathophysiology to food supplementation and clinical practice. Pharmacological Research (2025). ScienceDirect.
• Stigmasterol: An Enigmatic Plant Stress Sterol with Versatile Functions. International Journal of Molecular Sciences 25, no. 15 (2024): 8122. MDPI.
• Griebel T, Zeier J. "A role for beta-sitosterol to stigmasterol conversion in plant-pathogen interactions." Plant Journal 63, no. 2 (2010): 254–268. PubMed.
• Upjohn Steroid Medicines. American Chemical Society National Historic Chemical Landmarks.
• Effects of phytosterol supplementation on lipoprotein subfractions and LDL particle quality. Scientific Reports (2024). Nature.
• Effects of phytosterol-rich foods on lipid profile and inflammatory markers in patients with hyperlipidemia: a systematic review and meta-analysis. Frontiers in Pharmacology (2025). PMC12263549.
• Fageyinbo MS, et al. "Acanthospermum hispidum and Its Metabolite Stigmasterol Modulates Anti-Inflammatory Antagonism of COX-1 and TGF-β." Chemistry & Biodiversity 23, no. 1 (2026): e01647. Wiley.
• Stigmasterol. Wikipedia.